Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
Top Cited Papers
Open Access
- 12 March 2012
- journal article
- Published by Springer Science and Business Media LLC in Clinical Epigenetics
- Vol. 4 (1), 5
- https://doi.org/10.1186/1868-7083-4-5
Abstract
The zinc-dependent mammalian histone deacetylase (HDAC) family comprises 11 enzymes, which have specific and critical functions in development and tissue homeostasis. Mounting evidence points to a link between misregulated HDAC activity and many oncologic and nononcologic diseases. Thus the development of HDAC inhibitors for therapeutic treatment garners a lot of interest from academic researchers and biotechnology entrepreneurs. Numerous studies of HDAC inhibitor specificities and molecular mechanisms of action are ongoing. In one of these studies, mass spectrometry was used to characterize the affinities and selectivities of HDAC inhibitors toward native HDAC multiprotein complexes in cell extracts. Such a novel approach reproduces in vivo molecular interactions more accurately than standard studies using purified proteins or protein domains as targets and could be very useful in the isolation of inhibitors with superior clinical efficacy and decreased toxicity compared to the ones presently tested or approved. HDAC inhibitor induced-transcriptional reprogramming, believed to contribute largely to their therapeutic benefits, is achieved through various and complex mechanisms not fully understood, including histone deacetylation, transcription factor or regulator (including HDAC1) deacetylation followed by chromatin remodeling and positive or negative outcome regarding transcription initiation. Although only a very low percentage of protein-coding genes are affected by the action of HDAC inhibitors, about 40% of noncoding microRNAs are upregulated or downregulated. Moreover, a whole new world of long noncoding RNAs is emerging, revealing a new class of potential targets for HDAC inhibition. HDAC inhibitors might also regulate transcription elongation and have been shown to impinge on alternative splicing.Keywords
This publication has 120 references indexed in Scilit:
- Epigenetics in Alternative Pre-mRNA SplicingCell, 2011
- Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome StabilityCancer Cell, 2010
- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapyClinical Epigenetics, 2010
- Transcription factor co‐repressors in cancer biology: roles and targetingInternational Journal of Cancer, 2010
- Deacetylase Inhibitors Dissociate the Histone-Targeting ING2 Subunit from the Sin3 ComplexCell Chemical Biology, 2010
- Genome-wide Mapping of HATs and HDACs Reveals Distinct Functions in Active and Inactive GenesCell, 2009
- LSD1 Is a Subunit of the NuRD Complex and Targets the Metastasis Programs in Breast CancerCell, 2009
- Chromatin Modifications and Their FunctionCell, 2007
- Chromatin Challenges during DNA Replication and RepairCell, 2007
- Histone H3 Methylation by Set2 Directs Deacetylation of Coding Regions by Rpd3S to Suppress Spurious Intragenic TranscriptionCell, 2005